Dactinomycin – Uses, Dosage, Side Effects, Interaction

Last updated: February 8, 2026Reviewed date: February 8, 2026Reading time: 85 min read

Patient Tools

Read, save, and share this guide

Use these quick tools to make this medical article easier to read, print, save, or share with a family member.

On this page12 sections

Article Summary

Dactinomycin is an intravenously administered, antineoplastic antibiotic that is used in the treatment of solid tumors in children and choriocarcinoma in adult women. In high doses, dactinomycin can cause severe liver injury including sinusoidal obstruction syndrome. Dactinomycin is a chromopeptide antineoplastic antibiotic isolated from the bacterium Streptomyces parvulus. Dactinomycin intercalates between adjacent guanine-cytosine base pairs, blocking the transcription of DNA by RNA polymerase; it also causes...

Key Takeaways

This article explains Mechanism of Action in simple medical language.
This article explains Indications in simple medical language.
This article explains Contraindications in simple medical language.
This article explains Dosage in simple medical language.

Before reading

RX Patient Tools

Use these quick guides before reading the article, or return to them when you need help preparing questions for a doctor.

Start here Choose the right pathway for symptoms, reports, medicines, or urgent warning signs. Disease article roadmap Read this topic step by step: meaning, symptoms, warning signs, diagnosis, treatment, prevention, and follow-up. Treatment planner Prepare questions about treatment choices, benefits, risks, side effects, and follow-up. Family & caregiver guide Organize symptoms, reports, medicines, questions, and follow-up safely. Nutrition & diet guide Prepare food, hydration, supplement, and medicine-timing questions safely. Prevention guide Organize risk factors, protective habits, screening, and warning signs. Recovery guide Prepare a safe plan for activity, rehabilitation, warning signs, and follow-up.

Educational health guideWritten for patient understanding and clinical awareness.

Reviewed content workflowUse writer and reviewer profiles for stronger trust.

Emergency safety firstUrgent warning signs are highlighted below.

Choose your reading view

Patient View highlights a simple learning journey. Clinical View reveals structure, evidence, and editorial completeness.

Evidence Trust Passport

How this article is supported

79/100

Written byDr. Harun Ar Rashid, MD - Arthritis, Bones, Joints Pain, Trauma, and Internal Medicine Specialist

Medical review1 reviewer

Last reviewedNot scheduled

Next reviewNot scheduled

References1 source entry

Review statusReview schedule needed

Medical library classification Drug monograph Drugs A–Z

This passport makes the article’s review, evidence, and update signals visible. It does not guarantee that every section is complete or replace personal medical advice.

Definition

Dactinomycin is an intravenously administered, antineoplastic antibiotic that is used in the treatment of solid tumors in children and choriocarcinoma in adult women. In high doses, dactinomycin can cause severe liver injury including sinusoidal obstruction syndrome.

Dactinomycin is a chromopeptide antineoplastic antibiotic isolated from the bacterium Streptomyces parvulus. Dactinomycin intercalates between adjacent guanine–cytosine base pairs, blocking the transcription of DNA by RNA polymerase; it also causes single-strand DNA breaks, possibly via a free-radical intermediate or an interaction with topoisomerase II. (NCI04)

Dactinomycin is an Actinomycin. The mechanism of action of dactinomycin is as a Nucleic Acid Synthesis Inhibitor, and Protein Synthesis Inhibitor. A compound composed of two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)

Daptomycin is a cyclic lipopeptide antibiotic used to treat complicated skin and skin structure infections by susceptible Gram-positive bacteria and bacteremia due to Staphylococcus aureus. Daptomycin is a cyclic lipopeptide antibacterial agent with a broad spectrum of activity against Gram-positive bacteria, including methicillin-susceptible and -resistant Staphylococcus aureus (MSSA/MRSA) and vancomycin-resistant Enterococci (VRE). Chemically, daptomycin comprises 13 amino acids, including several non-standard and D-amino acids, with the C-terminal 10 amino acids forming an ester-linked ring and the N-terminal tryptophan covalently bonded to decanoic acid. Daptomycin was first discovered in the early 1980s by researchers at Eli Lilly in soil samples from Mount Ararat in Turkey.^[rx] Early work on developing daptomycin was abandoned due to observed myopathy but was resumed in 1997 when Cubist Pharmaceuticals Inc. licensed daptomycin; it was found that a once-daily dosing scheme reduced side effects while retaining efficacy.^[rx]

Daptomycin was approved by the FDA on September 12, 2003, and is marketed under the name CUBICIN® by Cubist Pharmaceuticals LLC (Merck & Co.).^[rx]

Mechanism of Action

Good evidence exists that this drug bind strongly, but reversibly, to DNA, interfering with synthesis of RNA (prevention of RNA polymerase elongation) and, consequently, with protein synthesis.

The capacity of actinomycins to bind with double-helical DNA is responsible for their biological activity and cytotoxicity. X-ray studies of a crystalline complex between dactinomycin and deoxyguanosine permitted formulation of a model that appears to explain the binding of the drug to DNA. The planar phenoxazone ring intercalates between adjacent guanine–cytosine base pairs of DNA, while the polypeptide chains extend along the minor groove of the helix. The summation of these interactions provides great stability to the dactinomycin-DNA complex, and as a result of the binding of dactinomycin, the transcription of DNA by RNA polymerase is blocked. The DNA-dependent RNA polymerases are much more sensitive to the effects of dactinomycin than are the DNA polymerases. In addition, dactinomycin causes single-strand breaks in DNA, possibly through a free-radical intermediate or as a result of the action of topoisomerase II

Dactinomycin is an antineoplastic antibiotic. The drug has bacteriostatic activity, particularly against gram-positive organisms, but its cytotoxicity precludes its use as an anti-infective agent. Although the exact mechanism(s) of action has not been fully elucidated, the drug appears to inhibit DNA-dependent RNA synthesis by forming a complex with DNA by intercalating with guanine residues and impairing the template activity of DNA. Protein and DNA synthesis are also inhibited but less extensively and at higher concentrations of dactinomycin than are needed to inhibit RNA synthesis. Dactinomycin is immunosuppressive and also possesses some hypocalcemic activity similar to plicamycin.

Generally, the actinomycins exert an inhibitory effect on gram-positive and gram-negative bacteria and on some fungi. However, the toxic properties of the actinomycins (including dactinomycin) in relation to antibacterial activity are such as to preclude their use as antibiotics in the treatment of infectious diseases. Because the actinomycins are cytotoxic, they have an antineoplastic effect which has been demonstrated in experimental animals with various types of tumor implant. This cytotoxic action is the basis for their use in the treatment of certain types of cancer. Dactinomycin is believed to produce its cytotoxic effects by binding DNA and inhibiting RNA synthesis.

Indications

Antineoplastic; Anti-Bacterial Agents; Nucleic Acid Synthesis Inhibitors; Protein Synthesis Inhibitors
For the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma, and metastatic, nonseminomatous testicular cancer as part of a combination chemotherapy and/or multi-modality treatment regimen.
Daptomycin is indicated for the treatment of complicated skin and skin structure infections (cSSSI) in patients one year of age and older. It is also indicated for the treatment of Staphylococcus aureus bloodstream infections (bacteremia) in patients one year of age and older, including in adult patients with right-sided infective endocarditis.^[rx]
Dactinomycin is an intravenously administered, antineoplastic antibiotic that is used in the treatment of solid tumors in children and choriocarcinoma in adult women.
Dactinomycin, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer.
Dactinomycin is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia.
Dactinomycin, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies.
Complicated Skin and Skin Structure Infection
Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)

Use in Cancer

Dactinomycin is approved to be used alone or with other drugs to treat:

Ewing sarcoma in adults and children.
Gestational trophoblastic disease in adults and children.
Rhabdomyosarcoma in adults and children.
Solid tumors that are locally recurrent. It is used as palliative and/or adjuvant therapy in adults.
Testicular cancer. It is used in adults and children whose nonseminomas have metastasized (spread to other parts of the body).
Wilms tumor in adults and children.

Dactinomycin is also being studied in the treatment of other types of cancer.

Contraindications

Serious rash.
New primary malignancy.
Anemia, bone marrow suppression, geriatric, neutropenia, thrombocytopenia.
Herpes infection, infection.
Extravasation.
Children, hepatotoxicity, infants, sinusoidal obstruction syndrome (SOS), veno-occlusive disease (VOD)
Radiation therapy.
shingles
a bad infection
low blood counts due to bone marrow failure
anemia
decreased blood platelets
low levels of white blood cells
low levels of a type of white blood cell called neutrophils
a blood clot in a vein of the liver
liver problems
ascites
abnormal liver function tests
pregnancy
a patient who is producing milk and breastfeeding
infection caused by the varicella zoster virus
exposure to the chickenpox

Dosage

Strengths: 0.5 mg

Wilms’ Tumor

As part of a multi-agent combination chemotherapy regimen: 45 mcg/kg IV over 10 to 15 minutes once every 3 to 6 weeks for up to 26 weeks
For the treatment of Wilms tumor as part of a multi-phase combination chemotherapy regimen

Rhabdomyosarcoma

As part of a multi-agent combination chemotherapy regimen: 15 mcg/kg IV over 10 to 15 minutes once daily for 5 days every 3 to 9 weeks for up to 112 weeks
For the treatment of rhabdomyosarcoma as part of a multi-phase combination chemotherapy regimen

Ewing’s Sarcoma

As part of a multi-agent combination chemotherapy regimen: 1250 mcg/m2 IV over 10 to 15 minutes once every 3 weeks for 51 weeks
For the treatment of Ewing sarcoma as part of a multi-phase combination chemotherapy regimen

Testicular Cancer

As part of a cisplatin-based multi-agent combination chemotherapy regimen: 1000 mcg/m2 IV over 10 to 15 minutes once every 3 weeks for 12 weeks
For the treatment of metastatic nonseminomatous testicular cancer as part of a multi-phase combination chemotherapy regimen

Trophoblastic Disease

As a single agent for nonmetastatic and low-risk metastatic disease: 12 mcg/kg IV over 10 to 15 minutes daily for 5 days
As part of a multi-agent combination chemotherapy regimen for high-risk metastatic disease: 500 mcg IV over 10 to 15 minutes Days 1 and 2 every 2 weeks for up to 8 weeks
For the treatment of post-menarchal patients with gestational trophoblastic neoplasia as a single agent or as part of a combination chemotherapy regimen

Solid Tumors

In combination with melphalan for lower extremity or pelvis: 50 mcg/kg IV over 10 to 15 minutes once
In combination with melphalan for upper extremity: 35 mcg/kg IV once
For the treatment of adult patients with locally recurrent or locoregional solid malignancies as a component of palliative or adjunctive regional perfusion

Usual Pediatric Dose

Wilms’ Tumor

As part of a multi-agent combination chemotherapy regimen: 45 mcg/kg IV over 10 to 15 minutes once every 3 to 6 weeks for up to 26 weeks
For the treatment of Wilms tumor as part of a multi-phase combination chemotherapy regimen

Rhabdomyosarcoma

As part of a multi-agent combination chemotherapy regimen: 15 mcg/kg IV over 10 to 15 minutes once daily for 5 days every 3 to 9 weeks for up to 112 weeks
For the treatment of rhabdomyosarcoma as part of a multi-phase combination chemotherapy regimen

Ewing’s Sarcoma

As part of a multi-agent combination chemotherapy regimen: 1250 mcg/m2 IV over 10 to 15 minutes once every 3 weeks for 51 weeks
For the treatment of Ewing sarcoma as part of a multi-phase combination chemotherapy regimen

Testicular Cancer

As part of a cisplatin-based multi-agent combination chemotherapy regimen: 1000 mcg/m2 IV over 10 to 15 minutes once every 3 weeks for 12 weeks
For the treatment of metastatic nonseminomatous testicular cancer as part of a multi-phase combination chemotherapy regimen

Trophoblastic Disease

As a single agent for nonmetastatic and low-risk metastatic disease: 12 mcg/kg IV over 10 to 15 minutes daily for 5 days
As part of a multi-agent combination chemotherapy regimen for high-risk metastatic disease: 500 mcg IV over 10 to 15 minutes Days 1 and 2 every 2 weeks for up to 8 weeks
For the treatment of post-menarchal pediatric patients with gestational trophoblastic neoplasia as a single agent or as part of a combination chemotherapy regimen

Dose Adjustments

Calculate the dose for obese or edematous patients based on ideal body weight.

Administration advice:

Administer the diluted reconstituted product IV over 10 to 15 minutes.
Do not use in-line filters with a cellulose ester membrane.

Side Effects

The Most Common

Common adverse drug reaction includes bone marrow suppression, fatigue, hair loss, mouth ulcer, loss of appetite and diarrhea. Actinomycin is a vesicant, if extravasation occurs.
vomiting
stomach pain
diarrhea
hair loss
hives
rash
difficulty breathing or swallowing
nausea
extreme tiredness
unusual bleeding or bruising
sores in the mouth and throat
lack of energy
loss of appetite
pain in the upper right part of the stomach
yellowing of the skin or eyes
fever, sore throat, ongoing cough and congestion, or other signs of infection
unusual bleeding or bruising
black and tarry stools
red blood in stools

More common

Black, tarry stools
blood in the urine or stools
chills
cough
diarrhea (continuing)
difficulty with swallowing
fever
heartburn
hoarseness
lower back or side pain
painful or difficult urination
pinpoint red spots on the skin
sores in the mouth and on the lips
stomach pain (continuing)
unusual bleeding or bruising
unusual tiredness or weakness
swelling or tenderness in your stomach (upper right side), rapid weight gain;
swelling in your arms or legs;
dark urine, jaundice (yellowing of the skin or eyes);
redness of your skin or the inside of your mouth and throat (if you are also receiving radiation treatment);
sores or white patches in or around your mouth, trouble swallowing or talking, dry mouth, bad breath, altered sense of taste;
blisters, ulcers, or other skin changes where an injection was given; or
low blood cell counts–fever, chills, tiredness, mouth sores, skin sores, easy bruising, unusual bleeding, pale skin, cold hands and feet, feeling light-headed or short of breath.

Rare

Blistering, peeling, or loosening of the skin
body aches or pain
chapped, red, or swollen lips
confusion
congestion
cough
difficulty with breathing
difficulty with moving
difficulty with swallowing
dryness or soreness of the throat
flushing or redness of the skin
irregular heartbeat
joint pain or swelling
muscle ache, pains, or stiffness
muscle cramps in the hands, arms, feet, legs, or face
numbness and tingling around the mouth, fingertips, or feet
pain at the injection site
runny nose
scaling, redness, burning, pain, or other signs of inflammation of the lips
seizures
slow growth
stomach cramps
swelling of the feet or lower legs
tender, swollen glands in the neck
tremor
unusually warm skin
voice changes
yellow eyes or skin

Drug Interaction

DRUG	INTERACTION
Abacavir	Daptomycin may decrease the excretion rate of Abacavir which could result in a higher serum level.
Abemaciclib	The serum concentration of Abemaciclib can be increased when it is combined with Daptomycin.
Abrocitinib	The serum concentration of Daptomycin can be increased when it is combined with Abrocitinib.
Aceclofenac	Aceclofenac may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Acemetacin	Acemetacin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Acenocoumarol	The risk or severity of bleeding can be increased when Daptomycin is combined with Acenocoumarol.
Acetaminophen	Daptomycin may decrease the excretion rate of Acetaminophen which could result in a higher serum level.
Acetazolamide	Acetazolamide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Acetylsalicylic acid	Acetylsalicylic acid may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Acipimox	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Acipimox.
Aclidinium	Daptomycin may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Acrivastine	Daptomycin may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Acyclovir	Acyclovir may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Adefovir dipivoxil	Adefovir dipivoxil may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Afatinib	The serum concentration of Daptomycin can be increased when it is combined with Afatinib.
Albutrepenonacog	Daptomycin may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.
Alclofenac	Alclofenac may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Aldesleukin	Aldesleukin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Alendronic acid	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Alendronic acid.
Allopurinol	Daptomycin may decrease the excretion rate of Allopurinol which could result in a higher serum level.
Almasilate	Daptomycin may decrease the excretion rate of Almasilate which could result in a higher serum level.
Almotriptan	Daptomycin may decrease the excretion rate of Almotriptan which could result in a higher serum level.
Alogliptin	Daptomycin may decrease the excretion rate of Alogliptin which could result in a higher serum level.
Alprazolam	Daptomycin may decrease the excretion rate of Alprazolam which could result in a higher serum level.
Amantadine	Daptomycin may decrease the excretion rate of Amantadine which could result in a higher serum level.
Ambrisentan	The serum concentration of Ambrisentan can be increased when it is combined with Daptomycin.
Amikacin	Daptomycin may decrease the excretion rate of Amikacin which could result in a higher serum level.
Amiloride	Amiloride may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Aminophenazone	Aminophenazone may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Amiodarone	The serum concentration of Daptomycin can be increased when it is combined with Amiodarone.
Amitriptyline	Daptomycin may decrease the excretion rate of Amitriptyline which could result in a higher serum level.
Ammonium chloride	Daptomycin may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.
Amoxicillin	Daptomycin may decrease the excretion rate of Amoxicillin which could result in a higher serum level.
Amphetamine	Daptomycin may decrease the excretion rate of Amphetamine which could result in a higher serum level.
Amphotericin B	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Amphotericin B.
Ampicillin	Daptomycin may decrease the excretion rate of Ampicillin which could result in a higher serum level.
Amrinone	Daptomycin may decrease the excretion rate of Amrinone which could result in a higher serum level.
Ancestim	Daptomycin may decrease the excretion rate of Ancestim which could result in a higher serum level.
Antihemophilic	Daptomycin may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.
Antipyrine	Antipyrine may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Antithrombin	Daptomycin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.
Antrafenine	Antrafenine may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Apalutamide	The serum concentration of Daptomycin can be decreased when it is combined with Apalutamide.
Apixaban	The serum concentration of Apixaban can be increased when it is combined with Daptomycin.
Apremilast	Daptomycin may decrease the excretion rate of Apremilast which could result in a higher serum level.
Arformoterol	Daptomycin may decrease the excretion rate of Arformoterol which could result in a higher serum level.
Arsenic trioxide	The serum concentration of Daptomycin can be increased when it is combined with Arsenic trioxide.
Articaine	The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Articaine.
Asciminib	The serum concentration of Daptomycin can be increased when it is combined with Asciminib.
Asunaprevir	The serum concentration of Daptomycin can be increased when it is combined with Asunaprevir.
Atazanavir	Atazanavir may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Atomoxetine	Daptomycin may decrease the excretion rate of Atomoxetine which could result in a higher serum level.
Atorvastatin	The risk or severity of myopathy can be increased when Atorvastatin is combined with Daptomycin.
Auranofin	Daptomycin may decrease the excretion rate of Auranofin which could result in a higher serum level.
Aurothioglucose	Daptomycin may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.
Avanafil	The serum concentration of Avanafil can be increased when it is combined with Daptomycin.
Avatrombopag	The serum concentration of Avatrombopag can be increased when it is combined with Daptomycin.
Axitinib	The serum concentration of Axitinib can be increased when it is combined with Daptomycin.
Azacitidine	Daptomycin may decrease the excretion rate of Azacitidine which could result in a higher serum level.
Azathioprine	Daptomycin may decrease the excretion rate of Azathioprine which could result in a higher serum level.
Azelaic acid	Daptomycin may decrease the excretion rate of Azelaic acid which could result in a higher serum level.
Aztreonam	Daptomycin may decrease the excretion rate of Aztreonam which could result in a higher serum level.
Bacitracin	Bacitracin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Baclofen	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Baclofen.
Balsalazide	Balsalazide may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Baricitinib	Daptomycin may decrease the excretion rate of Baricitinib which could result in a higher serum level.
BCG vaccine	The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Daptomycin.
Belantamab	The serum concentration of Belantamab mafodotin can be increased when it is combined with Daptomycin.
Belinostat	The serum concentration of Belinostat can be increased when it is combined with Daptomycin.
Belumosudil	The serum concentration of Daptomycin can be increased when it is combined with Belumosudil.
Bendamustine	The serum concentration of Bendamustine can be increased when it is combined with Daptomycin.
Bendroflumet	Bendroflumethiazide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Benorilate	Benorilate may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Benoxaprofen	Benoxaprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Benserazide	Daptomycin may decrease the excretion rate of Benserazide which could result in a higher serum level.
Benzatropine	Daptomycin may decrease the excretion rate of Benzatropine which could result in a higher serum level.
Benznidazole	Daptomycin may decrease the excretion rate of Benznidazole which could result in a higher serum level.
Benzocaine	The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Benzocaine.
Benzthiazide	Benzthiazide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Benzydamine	Benzydamine may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Benzyl alcohol	The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Benzyl alcohol.
Bepotastine	Daptomycin may decrease the excretion rate of Bepotastine which could result in a higher serum level.
Berotralstat	The serum concentration of Berotralstat can be increased when it is combined with Daptomycin.
Betamethasone	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Betamethasone.
Betrixaban	The serum concentration of Betrixaban can be increased when it is combined with Daptomycin.
Bezafibrate	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Bezafibrate.
Bicisate	Daptomycin may decrease the excretion rate of Bicisate which could result in a higher serum level.
Binimetinib	The serum concentration of Binimetinib can be increased when it is combined with Daptomycin.
Bismuth subgallate	Daptomycin may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level.
Bisoprolol	The serum concentration of Bisoprolol can be increased when it is combined with Daptomycin.
Bisoxatin	Daptomycin may decrease the excretion rate of Bisoxatin which could result in a higher serum level.
Bleomycin	Daptomycin may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Bortezomib	The serum concentration of Bortezomib can be increased when it is combined with Daptomycin.
Bosutinib	The serum concentration of Bosutinib can be increased when it is combined with Daptomycin.
Brentuximab vedotin	The serum concentration of Brentuximab vedotin can be increased when it is combined with Daptomycin.
Brivaracetam	Daptomycin may decrease the excretion rate of Brivaracetam which could result in a higher serum level.
Bromazepam	Daptomycin may decrease the excretion rate of Bromazepam which could result in a higher serum level.
Bromotheophylline	Bromotheophylline may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Budesonide	Daptomycin may decrease the excretion rate of Budesonide which could result in a higher serum level.
Bumadizone	Bumadizone may decrease the excretion rate of Daptomycin which could result in a higher serum level.

Bumetanide	Bumetanide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Bupivacaine	The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Bupivacaine.
Bupropion	Daptomycin may decrease the excretion rate of Bupropion which could result in a higher serum level.
Buspirone	Daptomycin may decrease the excretion rate of Buspirone which could result in a higher serum level.
Butabarbital	Daptomycin may decrease the excretion rate of Butabarbital which could result in a higher serum level.
Butacaine	The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Butacaine.
Butamben	The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Butamben.
Cabazitaxel	The serum concentration of Cabazitaxel can be increased when it is combined with Daptomycin.
Cabergoline	The serum concentration of Cabergoline can be increased when it is combined with Daptomycin.
Canagliflozin	The serum concentration of Daptomycin can be increased when it is combined with Canagliflozin.
Canrenoic acid	Canrenoic acid may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Capecitabine	Daptomycin may decrease the excretion rate of Capecitabine which could result in a higher serum level.
Capmatinib	The serum concentration of Daptomycin can be increased when it is combined with Capmatinib.
Capreomycin	Daptomycin may decrease the excretion rate of Capreomycin which could result in a higher serum level.
Capsaicin	The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Capsaicin.
Captopril	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Captopril.
Carbamazepine	Daptomycin may decrease the excretion rate of Carbamazepine which could result in a higher serum level.
Carbidopa	Daptomycin may decrease the excretion rate of Carbidopa which could result in a higher serum level.
Carbimazole	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Carbimazole.
Carboplatin	Carboplatin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Carfilzomib	The serum concentration of Daptomycin can be increased when it is combined with Carfilzomib.
Carmustine	Daptomycin may decrease the excretion rate of Carmustine which could result in a higher serum level.
Carprofen	Carprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Carvedilol	The serum concentration of Daptomycin can be increased when it is combined with Carvedilol.
Cefaclor	Cefaclor may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cefadroxil	Cefadroxil may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cefalotin	Cefalotin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cefamandole	Cefamandole may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cefapirin	Cefapirin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cefazolin	Cefazolin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cefdinir	Daptomycin may decrease the excretion rate of Cefdinir which could result in a higher serum level.
Cefditoren	Cefditoren may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cefepime	Cefepime may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cefmenoxime	Cefmenoxime may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cefmetazole	Cefmetazole may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cefonicid	Cefonicid may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cefoperazone	Cefoperazone may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Ceforanide	Ceforanide may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cefotaxime	Cefotaxime may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cefotetan	Cefotetan may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cefotiam	Cefotiam may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cefoxitin	Cefoxitin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cefpiramide	Cefpiramide may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cefpirome	Cefpirome may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cefpodoxime	Cefpodoxime may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cefprozil	Cefprozil may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cefradine	Cefradine may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Ceftaroline fosamil	Ceftaroline fosamil may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Ceftazidime	Ceftazidime may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Ceftibuten	Ceftibuten may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Ceftizoxime	Ceftizoxime may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Ceftobiprole	Ceftobiprole may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Ceftolozane	Daptomycin may decrease the excretion rate of Ceftolozane which could result in a higher serum level.
Ceftriaxone	Ceftriaxone may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cefuroxime	Cefuroxime may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Celecoxib	Celecoxib may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cephalexin	Cephalexin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cephaloglycin	Cephaloglycin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Ceritinib	The serum concentration of Ceritinib can be increased when it is combined with Daptomycin.
Cerivastatin	The risk or severity of myopathy can be increased when Cerivastatin is combined with Daptomycin.
Certolizumab pegol	Daptomycin may decrease the excretion rate of Certolizumab pegol which could result in a higher serum level.
Cetirizine	Daptomycin may decrease the excretion rate of Cetirizine which could result in a higher serum level.
Cevimeline	Daptomycin may decrease the excretion rate of Cevimeline which could result in a higher serum level.
Chloral hydrate	Daptomycin may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.
Chloroprocaine	The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Chloroprocaine.
Chloroquine	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Chloroquine.
Chlorothiazide	Chlorothiazide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Chloroxylenol	Daptomycin may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.
Chlorpromazine	Daptomycin may decrease the excretion rate of Chlorpromazine which could result in a higher serum level.
Chlorpropamide	Daptomycin may decrease the excretion rate of Chlorpropamide which could result in a higher serum level.
Chlorthalidone	Chlorthalidone may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Chlorzoxazone	Daptomycin may decrease the excretion rate of Chlorzoxazone which could result in a higher serum level.
Choline C 11	Daptomycin may decrease the excretion rate of Choline C 11 which could result in a higher serum level.
Choline magnesium	Choline magnesium trisalicylate may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Choline salicylate	Daptomycin may decrease the excretion rate of Choline salicylate which could result in a higher serum level.
Chondroitin sulfate	Daptomycin may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.
Chromic chloride	Daptomycin may decrease the excretion rate of Chromic chloride which could result in a higher serum level.
Chromic nitrate	Daptomycin may decrease the excretion rate of Chromic nitrate which could result in a higher serum level.
Chromium	Daptomycin may decrease the excretion rate of Chromium which could result in a higher serum level.
Chromium gluconate	Daptomycin may decrease the excretion rate of Chromium gluconate which could result in a higher serum level.
Chromium nicotinate	Daptomycin may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level.
Chromous sulfate	Daptomycin may decrease the excretion rate of Chromous sulfate which could result in a higher serum level.
Cidofovir	Cidofovir may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Cilostazol	Daptomycin may decrease the excretion rate of Cilostazol which could result in a higher serum level.
Cimetidine	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Cimetidine.
Cinchocaine	The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Cinchocaine.
Ciprofibrate	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ciprofibrate.
Ciprofloxacin	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ciprofloxacin.
Cisatracurium	Daptomycin may increase the neuromuscular blocking activities of Cisatracurium.
Cisplatin	Daptomycin may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Cladribine	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Cladribine.
Clarithromycin	The serum concentration of Daptomycin can be increased when it is combined with Clarithromycin.
Clevidipine	Daptomycin may decrease the excretion rate of Clevidipine which could result in a higher serum level.
Clobazam	The serum concentration of Clobazam can be increased when it is combined with Daptomycin.
Clofarabine	Daptomycin may decrease the excretion rate of Clofarabine which could result in a higher serum level.
Clofazimine	The serum concentration of Daptomycin can be increased when it is combined with Clofazimine.
Clofibrate	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Clofibrate.
Clomifene	The serum concentration of Clomifene can be increased when it is combined with Daptomycin.
Clomipramine	Daptomycin may decrease the excretion rate of Clomipramine which could result in a higher serum level.
Clonazepam	Daptomycin may decrease the excretion rate of Clonazepam which could result in a higher serum level.

Clorazepic acid	Daptomycin may decrease the excretion rate of Clorazepic acid which could result in a higher serum level.
Clove oil	Daptomycin may decrease the excretion rate of Clove oil which could result in a higher serum level.
Clozapine	Daptomycin may decrease the excretion rate of Clozapine which could result in a higher serum level.
Cobicistat	The serum concentration of Daptomycin can be increased when it is combined with Cobicistat.
Cobimetinib	The serum concentration of Cobimetinib can be increased when it is combined with Daptomycin.
Cocaine	The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Cocaine.
Colchicine	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Colchicine.
Colistimethate	Colistimethate may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Colistin	Daptomycin may decrease the excretion rate of Colistin which could result in a higher serum level.
Conivaptan	The serum concentration of Daptomycin can be increased when it is combined with Conivaptan.
C. estrogens	Daptomycin may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level.
Copanlisib	The serum concentration of Copanlisib can be increased when it is combined with Daptomycin.
Corifollitropin alfa	Daptomycin may decrease the excretion rate of Corifollitropin alfa which could result in a higher serum level.
Crizotinib	The serum concentration of Daptomycin can be increased when it is combined with Crizotinib.
Curcumin	The serum concentration of Daptomycin can be increased when it is combined with Curcumin.
Cyanocobalamin	Daptomycin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Cyclopenthiazide	Cyclopenthiazide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Cyclosporine	The serum concentration of Daptomycin can be increased when it is combined with Cyclosporine.
Cyclothiazide	Cyclothiazide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Cytarabine	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Cytarabine.
Dabigatran etexilate	The serum concentration of Dabigatran etexilate can be increased when it is combined with Daptomycin.
Dabrafenib	The serum concentration of Dabrafenib can be increased when it is combined with Daptomycin.
Dacarbazine	Daptomycin may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Daclatasvir	The serum concentration of Daptomycin can be increased when it is combined with Daclatasvir.
Dacomitinib	The serum concentration of Daptomycin can be increased when it is combined with Dacomitinib.
Dactinomycin	The serum concentration of Dactinomycin can be increased when it is combined with Daptomycin.
Dalfampridine	Daptomycin may decrease the excretion rate of Dalfampridine which could result in a higher serum level.
Dapagliflozin	Dapagliflozin may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Darolutamide	The serum concentration of Darolutamide can be increased when it is combined with Daptomycin.
Darunavir	The serum concentration of Darunavir can be increased when it is combined with Daptomycin.
Dasabuvir	The serum concentration of Dasabuvir can be increased when it is combined with Daptomycin.
Dasatinib	The serum concentration of Dasatinib can be increased when it is combined with Daptomycin.
Deferiprone	Daptomycin may decrease the excretion rate of Deferiprone which could result in a higher serum level.
Delafloxacin	Daptomycin may decrease the excretion rate of Delafloxacin which could result in a higher serum level.
Desipramine	Daptomycin may decrease the excretion rate of Desipramine which could result in a higher serum level.
Desmopressin	Desmopressin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Desvenlafaxine	Daptomycin may decrease the excretion rate of Desvenlafaxine which could result in a higher serum level.
Deutetrabenazine	Daptomycin may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.
Dexamethasone	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Dexamethasone.
Dexibuprofen	Dexibuprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Dexketoprofen	Dexketoprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Dexmedetomidine	Daptomycin may decrease the excretion rate of Dexmedetomidine which could result in a higher serum level.
Dexpanthenol	Daptomycin may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.
Dexrazoxane	Daptomycin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Dextran	Daptomycin may decrease the excretion rate of Dextran which could result in a higher serum level.
Diatrizoate	Daptomycin may decrease the excretion rate of Diatrizoate which could result in a higher serum level.
Diazepam	Daptomycin may decrease the excretion rate of Diazepam which could result in a higher serum level.
Dichlorobenzyl	Daptomycin may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.
Diclofenac	Diclofenac may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Diclofenamide	Diclofenamide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Dicoumarol	The risk or severity of bleeding can be increased when Daptomycin is combined with Dicoumarol.
Dicyclomine	Daptomycin may decrease the excretion rate of Dicyclomine which could result in a higher serum level.
Didanosine	Daptomycin may decrease the excretion rate of Didanosine which could result in a higher serum level.
Dienogest	Daptomycin may decrease the excretion rate of Dienogest which could result in a higher serum level.
Diflunisal	Diflunisal may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Difluocortolone	Daptomycin may decrease the excretion rate of Difluocortolone which could result in a higher serum level.
Digitoxin	The serum concentration of Digitoxin can be increased when it is combined with Daptomycin.
Digoxin	Daptomycin may decrease the excretion rate of Digoxin which could result in a higher serum level.
Dihydrostrep	Dihydrostreptomycin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Dimercaprol	Daptomycin may decrease the excretion rate of Dimercaprol which could result in a higher serum level.
Dimethyl sulfoxide	Daptomycin may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.
Diosmin	The serum concentration of Daptomycin can be increased when it is combined with Diosmin.
Diphenhydramine	The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Diphenhydramine.
Disopyramide	Daptomycin may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Methylephedrine	Daptomycin may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level.
Dobutamine	Daptomycin may decrease the excretion rate of Dobutamine which could result in a higher serum level.
Docetaxel	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Docetaxel.
Dolutegravir	The serum concentration of Dolutegravir can be increased when it is combined with Daptomycin.
Dopamine	Daptomycin may decrease the excretion rate of Dopamine which could result in a higher serum level.
Doripenem	Daptomycin may decrease the excretion rate of Doripenem which could result in a higher serum level.
Doxacurium	Daptomycin may decrease the excretion rate of Doxacurium which could result in a higher serum level.
Doxepin	Daptomycin may decrease the excretion rate of Doxepin which could result in a higher serum level.
Doxycycline	Daptomycin may decrease the excretion rate of Doxycycline which could result in a higher serum level.
Dronedarone	The serum concentration of Daptomycin can be increased when it is combined with Dronedarone.
Drospirenone	Drospirenone may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Droxidopa	Daptomycin may decrease the excretion rate of Droxidopa which could result in a higher serum level.
Duloxetine	Daptomycin may decrease the excretion rate of Duloxetine which could result in a higher serum level.
Duvelisib	The serum concentration of Duvelisib can be increased when it is combined with Daptomycin.
Dyclonine	The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Dyclonine.
Dyphylline	Daptomycin may decrease the excretion rate of Dyphylline which could result in a higher serum level.
Edoxaban	The serum concentration of Edoxaban can be increased when it is combined with Daptomycin.
Edrophonium	Daptomycin may decrease the excretion rate of Edrophonium which could result in a higher serum level.
Elagolix	The serum concentration of Daptomycin can be increased when it is combined with Elagolix.
Elbasvir	The serum concentration of Elbasvir can be increased when it is combined with Daptomycin.
Eliglustat	The serum concentration of Daptomycin can be increased when it is combined with Eliglustat.
Enalapril	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Enalapril.
Enalaprilat	Daptomycin may decrease the excretion rate of Enalaprilat which could result in a higher serum level.
Enasidenib	The serum concentration of Daptomycin can be increased when it is combined with Enasidenib.
Enfortumab vedotin	The serum concentration of Enfortumab vedotin can be increased when it is combined with Daptomycin.
Entrectinib	The serum concentration of Daptomycin can be increased when it is combined with Entrectinib.
Enzalutamide	Daptomycin may decrease the excretion rate of Enzalutamide which could result in a higher serum level.
Eplerenone	Eplerenone may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Epoprostenol	Daptomycin may decrease the excretion rate of Epoprostenol which could result in a higher serum level.
Eprosartan	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Eprosartan.
Erdafitinib	The serum concentration of Daptomycin can be increased when it is combined with Erdafitinib.
Ertapenem	Daptomycin may decrease the excretion rate of Ertapenem which could result in a higher serum level.
Ertugliflozin	Ertugliflozin may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Erythromycin	The serum concentration of Daptomycin can be increased when it is combined with Erythromycin.
Estazolam	Daptomycin may decrease the excretion rate of Estazolam which could result in a higher serum level.
Estetrol	The therapeutic efficacy of Estetrol can be decreased when used in combination with Daptomycin.

Estradiol	Daptomycin may decrease the excretion rate of Estradiol which could result in a higher serum level.
Estradiol acetate	Daptomycin may decrease the excretion rate of Estradiol acetate which could result in a higher serum level.
Estradiol cypionate	Daptomycin may decrease the excretion rate of Estradiol cypionate which could result in a higher serum level.
Estradiol dienanthate	Daptomycin may decrease the excretion rate of Estradiol dienanthate which could result in a higher serum level.
Estradiol valerate	Daptomycin may decrease the excretion rate of Estradiol valerate which could result in a higher serum level.
Estrone sulfate	Daptomycin may decrease the excretion rate of Estrone sulfate which could result in a higher serum level.
Eszopiclone	Daptomycin may decrease the excretion rate of Eszopiclone which could result in a higher serum level.
Etacrynic acid	Etacrynic acid may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Etafedrine	Daptomycin may decrease the excretion rate of Etafedrine which could result in a higher serum level.
Ethambutol	Daptomycin may decrease the excretion rate of Ethambutol which could result in a higher serum level.
Ethanol	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ethanol.
Ethyl chloride	The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Ethyl chloride.
Etidocaine	The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Etidocaine.
Etodolac	Etodolac may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Etomidate	Daptomycin may decrease the excretion rate of Etomidate which could result in a higher serum level.
Etonogestrel	Daptomycin may decrease the excretion rate of Etonogestrel which could result in a higher serum level.
Etoposide	The serum concentration of Etoposide can be increased when it is combined with Daptomycin.
Etoricoxib	Etoricoxib may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Eucalyptus oil	Daptomycin may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Everolimus	The serum concentration of Daptomycin can be increased when it is combined with Everolimus.
Ezogabine	Daptomycin may decrease the excretion rate of Ezogabine which could result in a higher serum level.
Favipiravir	The serum concentration of Daptomycin can be increased when it is combined with Favipiravir.
Fedratinib	The serum concentration of Daptomycin can be increased when it is combined with Fedratinib.
Fenbufen	Fenbufen may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Fenofibrate	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Fenofibrate.
Fenofibric acid	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Fenofibric acid.
Fenoldopam	Daptomycin may decrease the excretion rate of Fenoldopam which could result in a higher serum level.
Fenoprofen	Fenoprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Fentanyl	Daptomycin may decrease the excretion rate of Fentanyl which could result in a higher serum level.
Fesoterodine	Daptomycin may decrease the excretion rate of Fesoterodine which could result in a higher serum level.
Fexofenadine	The serum concentration of Fexofenadine can be increased when it is combined with Daptomycin.
Finerenone	Finerenone may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Flavoxate	Daptomycin may decrease the excretion rate of Flavoxate which could result in a higher serum level.
Flibanserin	The serum concentration of Daptomycin can be increased when it is combined with Flibanserin.
Floctafenine	Floctafenine may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Florbetaben	Daptomycin may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.
Florbetapir	Daptomycin may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.
Floxuridine	Daptomycin may decrease the excretion rate of Floxuridine which could result in a higher serum level.
Fluconazole	The serum concentration of Daptomycin can be increased when it is combined with Fluconazole.
Flucytosine	Daptomycin may decrease the excretion rate of Flucytosine which could result in a higher serum level.
Fludeoxyglucose	Daptomycin may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.
Fluindione	The risk or severity of bleeding can be increased when Daptomycin is combined with Fluindione.
Flumazenil	Daptomycin may decrease the excretion rate of Flumazenil which could result in a higher serum level.
Fluocinolone	Daptomycin may decrease the excretion rate of Fluocinolone acetonide which could result in a higher serum level.
Flurazepam	Daptomycin may decrease the excretion rate of Flurazepam which could result in a higher serum level.
Flurbiprofen	Flurbiprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Flutamide	Daptomycin may decrease the excretion rate of Flutamide which could result in a higher serum level.
Fluvastatin	The risk or severity of myopathy can be increased when Fluvastatin is combined with Daptomycin.
Fluvoxamine	Daptomycin may decrease the excretion rate of Fluvoxamine which could result in a higher serum level.
Folic acid	Daptomycin may decrease the excretion rate of Folic acid which could result in a higher serum level.
Fomepizole	Daptomycin may decrease the excretion rate of Fomepizole which could result in a higher serum level.
Fondaparinux	Daptomycin may decrease the excretion rate of Fondaparinux which could result in a higher serum level.
Formestane	Daptomycin may decrease the excretion rate of Formestane which could result in a higher serum level.
Foscarnet	Foscarnet may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Fosfomycin	Daptomycin may decrease the excretion rate of Fosfomycin which could result in a higher serum level.
Fosinopril	Daptomycin may decrease the excretion rate of Fosinopril which could result in a higher serum level.
Fostemsavir	The serum concentration of Fostemsavir can be increased when it is combined with Daptomycin.
Framycetin	Framycetin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Furosemide	Furosemide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Fusidic acid	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Fusidic acid.
Futibatinib	The serum concentration of Futibatinib can be increased when it is combined with Daptomycin.
Gabapentin	Daptomycin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.
Gadobenic acid	Daptomycin may decrease the excretion rate of Gadobenic acid which could result in a higher serum level.
Gadodiamide	Daptomycin may decrease the excretion rate of Gadodiamide which could result in a higher serum level.
Gadofosveset	Daptomycin may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.
Gadopentetic acid	Daptomycin may decrease the excretion rate of Gadopentetic acid which could result in a higher serum level.
Gadoteric acid	Daptomycin may decrease the excretion rate of Gadoteric acid which could result in a higher serum level.
Gadoteridol	Daptomycin may decrease the excretion rate of Gadoteridol which could result in a higher serum level.
Ganciclovir	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ganciclovir.
Gemcitabine	The serum concentration of Gemcitabine can be increased when it is combined with Daptomycin.
Gemfibrozil	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Gemfibrozil.
Gentamicin	Daptomycin may decrease the excretion rate of Gentamicin which could result in a higher serum level.
Gilteritinib	The serum concentration of Gilteritinib can be increased when it is combined with Daptomycin.
Gimeracil	Daptomycin may decrease the excretion rate of Gimeracil which could result in a higher serum level.
Givosiran	Givosiran may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Glasdegib	The serum concentration of Daptomycin can be increased when it is combined with Glasdegib.
Glecaprevir	The serum concentration of Daptomycin can be increased when it is combined with Glecaprevir.
Glipizide	Daptomycin may decrease the excretion rate of Glipizide which could result in a higher serum level.
Glycerol	Daptomycin may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.
Golodirsen	Daptomycin may decrease the excretion rate of Golodirsen which could result in a higher serum level.
Goserelin	Goserelin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Grazoprevir	The serum concentration of Grazoprevir can be increased when it is combined with Daptomycin.
Guanethidine	Daptomycin may decrease the excretion rate of Guanethidine which could result in a higher serum level.
Guanfacine	Daptomycin may decrease the excretion rate of Guanfacine which could result in a higher serum level.
Haloperidol	Daptomycin may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Hydralazine	Daptomycin may decrease the excretion rate of Hydralazine which could result in a higher serum level.
Hydrochlorothiazide	Hydrochlorothiazide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Hydroflumethiazide	Hydroflumethiazide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Hydromorphone	Daptomycin may decrease the excretion rate of Hydromorphone which could result in a higher serum level.
Hydroxocobalamin	Daptomycin may decrease the excretion rate of Hydroxocobalamin which could result in a higher serum level.
Hydroxyethyl Starch	Daptomycin may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.
Ibandronate	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ibandronate.
Ibuprofen	Ibuprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Ibutilide	Daptomycin may decrease the excretion rate of Ibutilide which could result in a higher serum level.
Icatibant	Daptomycin may decrease the excretion rate of Icatibant which could result in a higher serum level.
Icosapent	Icosapent may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Idarucizumab	Daptomycin may decrease the excretion rate of Idarucizumab which could result in a higher serum level.
Idebenone	Daptomycin may decrease the excretion rate of Idebenone which could result in a higher serum level.
Idelalisib	The serum concentration of Idelalisib can be increased when it is combined with Daptomycin.
Ifosfamide	Daptomycin may decrease the excretion rate of Ifosfamide which could result in a higher serum level.

Iloprost	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Iloprost.
Imipramine	The serum concentration of Imipramine can be increased when it is combined with Daptomycin.
Indacaterol	The serum concentration of Indacaterol can be increased when it is combined with Daptomycin.
Indapamide	Indapamide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Indigotindisulfonic	Daptomycin may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.
Indinavir	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Indinavir.
Indomethacin	Indomethacin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Infliximab	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Daptomycin.
Inosine pranobex	Daptomycin may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.
Inositol	Daptomycin may decrease the excretion rate of Inositol which could result in a higher serum level.
Inotersen	Inotersen may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Inotuzumab	The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Daptomycin.
Iobenguane sulfate	Daptomycin may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.
Iodixanol	Daptomycin may decrease the excretion rate of Iodixanol which could result in a higher serum level.
Ioflupane	Daptomycin may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.
Iopromide	Daptomycin may decrease the excretion rate of Iopromide which could result in a higher serum level.
Iothalamic acid	Daptomycin may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.
Ioversol	Daptomycin may decrease the excretion rate of Ioversol which could result in a higher serum level.
Ioxilan	Daptomycin may decrease the excretion rate of Ioxilan which could result in a higher serum level.
Ipecac	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ipecac.
Ipilimumab	Daptomycin may decrease the excretion rate of Ipilimumab which could result in a higher serum level.
Isavuconazole	The serum concentration of Daptomycin can be increased when it is combined with Isavuconazole.
Isavuconazonium	The serum concentration of Daptomycin can be increased when it is combined with Isavuconazonium.
Isoniazid	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Isoniazid.
Isosorbide	Isosorbide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Isosorbide	Daptomycin may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.
Isosulfan blue	Daptomycin may decrease the excretion rate of Isosulfan blue which could result in a higher serum level.
Isotretinoin	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Isotretinoin.
Isoxicam	Isoxicam may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Isradipine	Daptomycin may decrease the excretion rate of Isradipine which could result in a higher serum level.
Istradefylline	The serum concentration of Daptomycin can be increased when it is combined with Istradefylline.
Itraconazole	The serum concentration of Daptomycin can be increased when it is combined with Itraconazole.
Ivacaftor	The serum concentration of Daptomycin can be increased when it is combined with Ivacaftor.
Ivermectin	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ivermectin.
Ixabepilone	The serum concentration of Daptomycin can be increased when it is combined with Ixabepilone.
Ixazomib	Daptomycin may decrease the excretion rate of Ixazomib which could result in a higher serum level.
Kanamycin	Daptomycin may decrease the excretion rate of Kanamycin which could result in a higher serum level.
Ketamine	Daptomycin may decrease the excretion rate of Ketamine which could result in a higher serum level.
Ketazolam	Daptomycin may decrease the excretion rate of Ketazolam which could result in a higher serum level.
Ketoconazole	The serum concentration of Daptomycin can be increased when it is combined with Ketoconazole.
Ketoprofen	Ketoprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Ketorolac	Ketorolac may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Labetalol	Daptomycin may decrease the excretion rate of Labetalol which could result in a higher serum level.
Lamivudine	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Lamivudine.
Lamotrigine	Daptomycin may decrease the excretion rate of Lamotrigine which could result in a higher serum level.
Lapatinib	The serum concentration of Daptomycin can be increased when it is combined with Lapatinib.
Larotrectinib	The serum concentration of Larotrectinib can be increased when it is combined with Daptomycin.
Lasmiditan	The serum concentration of Daptomycin can be increased when it is combined with Lasmiditan.
Latamoxef	Latamoxef may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Ledipasvir	The serum concentration of Daptomycin can be increased when it is combined with Ledipasvir.
Lefamulin	The serum concentration of Lefamulin can be increased when it is combined with Daptomycin.
Leflunomide	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Leflunomide.
Lemborexant	The serum concentration of Lemborexant can be increased when it is combined with Daptomycin.
Lenalidomide	Daptomycin may decrease the excretion rate of Lenalidomide which could result in a higher serum level.
Lenvatinib	The serum concentration of Lenvatinib can be increased when it is combined with Daptomycin.
Lercanidipine	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Lercanidipine.
Lesinurad	Daptomycin may decrease the excretion rate of Lesinurad which could result in a higher serum level.
Letrozole	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Letrozole.
Leuprolide	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Daptomycin.
Levobupivacaine	The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Levobupivacaine.
Levocarnitine	Daptomycin may decrease the excretion rate of Levocarnitine which could result in a higher serum level.
Levocetirizine	Daptomycin may decrease the excretion rate of Levocetirizine which could result in a higher serum level.
Levofloxacin	Daptomycin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.
Levoketoconazole	The serum concentration of Daptomycin can be increased when it is combined with Levoketoconazole.
Levomilnacipran	Daptomycin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Levosalbutamol	Daptomycin may decrease the excretion rate of Levosalbutamol which could result in a higher serum level.
Lidocaine	The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Lidocaine.
Linagliptin	The serum concentration of Daptomycin can be increased when it is combined with Linagliptin.
Liothyronine	Daptomycin may decrease the excretion rate of Liothyronine which could result in a higher serum level.
Lisinopril	Daptomycin may decrease the excretion rate of Lisinopril which could result in a higher serum level.
Lithium carbonate	Daptomycin may decrease the excretion rate of Lithium carbonate which could result in a higher serum level.
Lithium citrate	Lithium citrate may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Lixisenatide	Daptomycin may decrease the excretion rate of Lixisenatide which could result in a higher serum level.
Lofexidine	Daptomycin may decrease the excretion rate of Lofexidine which could result in a higher serum level.
Lomitapide	The serum concentration of Daptomycin can be increased when it is combined with Lomitapide.
Lonafarnib	The serum concentration of Daptomycin can be increased when it is combined with Lonafarnib.
Loncastuximab	The serum concentration of Loncastuximab tesirine can be increased when it is combined with Daptomycin.
Loperamide	The serum concentration of Loperamide can be increased when it is combined with Daptomycin.
Lopinavir	The serum concentration of Daptomycin can be increased when it is combined with Lopinavir.
Loracarbef	Loracarbef may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Lorazepam	Daptomycin may decrease the excretion rate of Lorazepam which could result in a higher serum level.
Lorcaserin	Daptomycin may decrease the excretion rate of Lorcaserin which could result in a higher serum level.
Lornoxicam	Lornoxicam may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Lorpiprazole	Daptomycin may decrease the excretion rate of Lorpiprazole which could result in a higher serum level.
Lovastatin	The risk or severity of myopathy can be increased when Lovastatin is combined with Daptomycin.
Loxapine	The serum concentration of Daptomycin can be increased when it is combined with Loxapine.
Loxoprofen	Loxoprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Lubiprostone	Daptomycin may decrease the excretion rate of Lubiprostone which could result in a higher serum level.
Lumacaftor	The serum concentration of Daptomycin can be decreased when it is combined with Lumacaftor.
Lumiracoxib	Lumiracoxib may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Lusutrombopag	The serum concentration of Lusutrombopag can be increased when it is combined with Daptomycin.
Macitentan	Daptomycin may decrease the excretion rate of Macitentan which could result in a higher serum level.
Magnesium carbonate	Daptomycin may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.
Magnesium chloride	Daptomycin may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.
Magnesium	Daptomycin may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.
Magnesium trisilicate	Daptomycin may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level.
Mangafodipir	Daptomycin may decrease the excretion rate of Mangafodipir which could result in a higher serum level.
Mannitol	Mannitol may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Maprotiline	Daptomycin may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Maribavir	The serum concentration of Daptomycin can be increased when it is combined with Maribavir.

Mebeverine	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Mebeverine.
Mecamylamine	Daptomycin may decrease the excretion rate of Mecamylamine which could result in a higher serum level.
Meclofenamic acid	Meclofenamic acid may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Medroxyprogesterone	Daptomycin may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.
Mefenamic acid	Mefenamic acid may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Mefloquine	The serum concentration of Daptomycin can be increased when it is combined with Mefloquine.
Megestrol acetate	Daptomycin may decrease the excretion rate of Megestrol acetate which could result in a higher serum level.
Meloxicam	The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Meloxicam.
Memantine	Daptomycin may decrease the excretion rate of Memantine which could result in a higher serum level.
Meperidine	Daptomycin may decrease the excretion rate of Meperidine which could result in a higher serum level.
Mepivacaine	The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Mepivacaine.
Meropenem	Daptomycin may decrease the excretion rate of Meropenem which could result in a higher serum level.
Mesalazine	Mesalazine may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Metamfetamine	Daptomycin may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Metamizole	Metamizole may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Metaxalone	Daptomycin may decrease the excretion rate of Metaxalone which could result in a higher serum level.
Metformin	Daptomycin may decrease the excretion rate of Metformin which could result in a higher serum level.
Methadone	Daptomycin may decrease the excretion rate of Methadone which could result in a higher serum level.
Methazolamide	Methazolamide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Methimazole	Daptomycin may decrease the excretion rate of Methimazole which could result in a higher serum level.
Methotrexate	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Methotrexate.
Methoxsalen	Daptomycin may decrease the excretion rate of Methoxsalen which could result in a higher serum level.
Methyldopa	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Methyldopa.
Methylene blue	The serum concentration of Daptomycin can be increased when it is combined with Methylene blue.
Methylnaltrexone	Daptomycin may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level.
Methyltestosterone	Daptomycin may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.
Meticrane	Meticrane may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Metoclopramide	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Metoclopramide.
Metolazone	Metolazone may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Metoprolol	Daptomycin may decrease the excretion rate of Metoprolol which could result in a higher serum level.
Metyrapone	Daptomycin may decrease the excretion rate of Metyrapone which could result in a higher serum level.
Midazolam	Daptomycin may decrease the excretion rate of Midazolam which could result in a higher serum level.
Mifepristone	The serum concentration of Daptomycin can be increased when it is combined with Mifepristone.
Migalastat	Daptomycin may decrease the excretion rate of Migalastat which could result in a higher serum level.
Milnacipran	Daptomycin may decrease the excretion rate of Milnacipran which could result in a higher serum level.
Milrinone	Daptomycin may decrease the excretion rate of Milrinone which could result in a higher serum level.
Minocycline	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Minocycline.
Mirabegron	The serum concentration of Daptomycin can be increased when it is combined with Mirabegron.
Mitapivat	The serum concentration of Daptomycin can be increased when it is combined with Mitapivat.
Montelukast	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Montelukast.
Morphine	The serum concentration of Morphine can be increased when it is combined with Daptomycin.
Moxisylyte	Daptomycin may decrease the excretion rate of Moxisylyte which could result in a higher serum level.
Muzolimine	Muzolimine may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Mycophenolate	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Mycophenolate mofetil.
Mycophenolic acid	Daptomycin may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.
N-acetyltyrosine	Daptomycin may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level.
Nabumetone	Nabumetone may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Nadolol	Daptomycin may decrease the excretion rate of Nadolol which could result in a higher serum level.
Nafarelin	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Nafarelin.
Naldemedine	Daptomycin may decrease the excretion rate of Naldemedine which could result in a higher serum level.
Nalmefene	Daptomycin may decrease the excretion rate of Nalmefene which could result in a higher serum level.
Naloxone	Daptomycin may decrease the excretion rate of Naloxone which could result in a higher serum level.
Naltrexone	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Naltrexone.
Naproxen	Naproxen may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Nateglinide	Daptomycin may decrease the excretion rate of Nateglinide which could result in a higher serum level.
Nedaplatin	Daptomycin may decrease the excretion rate of Nedaplatin which could result in a higher serum level.
Nedocromil	Daptomycin may decrease the excretion rate of Nedocromil which could result in a higher serum level.
Nefazodone	Daptomycin may decrease the excretion rate of Nefazodone which could result in a higher serum level.
Neomycin	Daptomycin may decrease the excretion rate of Neomycin which could result in a higher serum level.
Neratinib	The serum concentration of Daptomycin can be increased when it is combined with Neratinib.
Netilmicin	Daptomycin may decrease the excretion rate of Netilmicin which could result in a higher serum level.
Netupitant	The serum concentration of Daptomycin can be increased when it is combined with Netupitant.
Niacin	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Niacin.
Nicorandil	Daptomycin may decrease the excretion rate of Nicorandil which could result in a higher serum level.
Nifedipine	Daptomycin may decrease the excretion rate of Nifedipine which could result in a higher serum level.
Nilotinib	The serum concentration of Daptomycin can be increased when it is combined with Nilotinib.
Nilutamide	Daptomycin may decrease the excretion rate of Nilutamide which could result in a higher serum level.
Nimesulide	Nimesulide may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Nintedanib	The serum concentration of Nintedanib can be increased when it is combined with Daptomycin.
Nisoldipine	Daptomycin may decrease the excretion rate of Nisoldipine which could result in a higher serum level.
Nitric Oxide	Daptomycin may decrease the excretion rate of Nitric Oxide which could result in a higher serum level.
Nitrofurantoin	Daptomycin may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.
Nitroprusside	Daptomycin may decrease the excretion rate of Nitroprusside which could result in a higher serum level.
Nizatidine	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Nizatidine.
Norfloxacin	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Norfloxacin.
Norgestimate	The serum concentration of Daptomycin can be increased when it is combined with Norgestimate.
Nortriptyline	The serum concentration of Nortriptyline can be increased when it is combined with Daptomycin.
Octinoxate	Daptomycin may decrease the excretion rate of Octinoxate which could result in a higher serum level.
Ofloxacin	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ofloxacin.
Olsalazine	Olsalazine may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Omadacycline	The serum concentration of Omadacycline can be increased when it is combined with Daptomycin.
Ombitasvir	The serum concentration of Ombitasvir can be increased when it is combined with Daptomycin.
Opium	Daptomycin may decrease the excretion rate of Opium which could result in a higher serum level.
Oseltamivir	Daptomycin may decrease the excretion rate of Oseltamivir which could result in a higher serum level.
Osimertinib	The serum concentration of Osimertinib can be increased when it is combined with Daptomycin.
Oxacillin	Daptomycin may decrease the excretion rate of Oxacillin which could result in a higher serum level.
Oxaprozin	Oxaprozin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Oxazepam	Daptomycin may decrease the excretion rate of Oxazepam which could result in a higher serum level.
Oxetacaine	The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Oxetacaine.
Oxybenzone	Daptomycin may decrease the excretion rate of Oxybenzone which could result in a higher serum level.
Oxybuprocaine	The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Oxybuprocaine.
Oxyphenbutazone	Oxyphenbutazone may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Oxyquinoline	Daptomycin may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.
Paclitaxel	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Paclitaxel.
Pacritinib	The serum concentration of Daptomycin can be increased when it is combined with Pacritinib.
Palbociclib	The serum concentration of Daptomycin can be increased when it is combined with Palbociclib.
Paliperidone	The serum concentration of Daptomycin can be increased when it is combined with Paliperidone.
Palonosetron	Daptomycin may decrease the excretion rate of Palonosetron which could result in a higher serum level.
Pamidronic acid	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Pamidronic acid.
Panobinostat	The serum concentration of Panobinostat can be increased when it is combined with Daptomycin.

Pantoprazole	Daptomycin may decrease the excretion rate of Pantoprazole which could result in a higher serum level.
Parecoxib	Parecoxib may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Paritaprevir	The serum concentration of Paritaprevir can be increased when it is combined with Daptomycin.
Paromomycin	Paromomycin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Patent Blue	Daptomycin may decrease the excretion rate of Patent Blue which could result in a higher serum level.
Pazopanib	The serum concentration of Pazopanib can be increased when it is combined with Daptomycin.
Pegaptanib	Daptomycin may decrease the excretion rate of Pegaptanib which could result in a higher serum level.
Peginesatide	Daptomycin may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Pemetrexed	Daptomycin may decrease the excretion rate of Pemetrexed which could result in a higher serum level.
Penbutolol	Daptomycin may decrease the excretion rate of Penbutolol which could result in a higher serum level.
Penicillamine	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Penicillamine.
Pentaerythritol	Daptomycin may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.
Pentamidine	Pentamidine may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Pentastarch	Daptomycin may decrease the excretion rate of Pentastarch which could result in a higher serum level.
Pentetic acid	Daptomycin may decrease the excretion rate of Pentetic acid which could result in a higher serum level.
Pentobarbital	Daptomycin may decrease the excretion rate of Pentobarbital which could result in a higher serum level.
Pentostatin	Daptomycin may decrease the excretion rate of Pentostatin which could result in a higher serum level.
Pentoxifylline	Daptomycin may decrease the excretion rate of Pentoxifylline which could result in a higher serum level.
Perindopril	Daptomycin may decrease the excretion rate of Perindopril which could result in a higher serum level.
Permethrin	Daptomycin may decrease the excretion rate of Permethrin which could result in a higher serum level.
Phenazopyridine	Phenazopyridine may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Phenelzine	Daptomycin may decrease the excretion rate of Phenelzine which could result in a higher serum level.
Phenindione	The risk or severity of bleeding can be increased when Daptomycin is combined with Phenindione.
Phenol	The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Phenol.
Phenprocoumon	The risk or severity of bleeding can be increased when Daptomycin is combined with Phenprocoumon.
Phentolamine	Daptomycin may decrease the excretion rate of Phentolamine which could result in a higher serum level.
Phenylbutazone	Phenylbutazone may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Phenytoin	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Phenytoin.
Pholcodine	Daptomycin may decrease the excretion rate of Pholcodine which could result in a higher serum level.
Phosphoric acid	Daptomycin may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.
Phylloquinone	Daptomycin may decrease the excretion rate of Phylloquinone which could result in a higher serum level.
Pibrentasvir	The serum concentration of Daptomycin can be increased when it is combined with Pibrentasvir.
Picosulfuric acid	Daptomycin may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level.
Pindolol	Daptomycin may decrease the excretion rate of Pindolol which could result in a higher serum level.
Piperacillin	Daptomycin may decrease the excretion rate of Piperacillin which could result in a higher serum level.
Piracetam	Daptomycin may decrease the excretion rate of Piracetam which could result in a higher serum level.
Piretanide	Piretanide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Piroxicam	Piroxicam may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Pitavastatin	The risk or severity of myopathy can be increased when Pitavastatin is combined with Daptomycin.
Pitolisant	The serum concentration of Daptomycin can be increased when it is combined with Pitolisant.
Plazomicin	Daptomycin may decrease the excretion rate of Plazomicin which could result in a higher serum level.
Plerixafor	Daptomycin may decrease the excretion rate of Plerixafor which could result in a higher serum level.
Polythiazide	Polythiazide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Pomalidomide	The serum concentration of Pomalidomide can be increased when it is combined with Daptomycin.
Ponatinib	The serum concentration of Daptomycin can be increased when it is combined with Ponatinib.
Posaconazole	The serum concentration of Posaconazole can be increased when it is combined with Daptomycin.
Potassium	Potassium may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Potassium acetate	Daptomycin may decrease the excretion rate of Potassium acetate which could result in a higher serum level.
Potassium bicarbonate	Daptomycin may decrease the excretion rate of Potassium bicarbonate which could result in a higher serum level.
Potassium cation	Potassium cation may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Potassium chloride	Daptomycin may decrease the excretion rate of Potassium chloride which could result in a higher serum level.
Potassium citrate	Potassium citrate may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Potassium nitrate	Daptomycin may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.
Potassium perchlorate	Daptomycin may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.
Potassium sulfate	Daptomycin may decrease the excretion rate of Potassium sulfate which could result in a higher serum level.
Pralatrexate	Daptomycin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Pralidoxime	Daptomycin may decrease the excretion rate of Pralidoxime which could result in a higher serum level.
Pralsetinib	The serum concentration of Daptomycin can be increased when it is combined with Pralsetinib.
Pramipexole	Daptomycin may decrease the excretion rate of Pramipexole which could result in a higher serum level.
Pramocaine	The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Pramocaine.
Prasugrel	Daptomycin may decrease the excretion rate of Prasugrel which could result in a higher serum level.
Pravastatin	The risk or severity of myopathy can be increased when Pravastatin is combined with Daptomycin.
Prednisolone phosphate	The serum concentration of Prednisolone phosphate can be increased when it is combined with Daptomycin.
Prednisone	Daptomycin may decrease the excretion rate of Prednisone which could result in a higher serum level.
Pregabalin	Daptomycin may decrease the excretion rate of Pregabalin which could result in a higher serum level.
Prilocaine	The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Prilocaine.
Probenecid	Daptomycin may decrease the excretion rate of Probenecid which could result in a higher serum level.
Procainamide	Daptomycin may decrease the excretion rate of Procainamide which could result in a higher serum level.
Procaine	The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Procaine.
Procaine benzylpenicillin	Daptomycin may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.
Procarbazine	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Procarbazine.
Promethazine	Daptomycin may decrease the excretion rate of Promethazine which could result in a higher serum level.
Propafenone	The serum concentration of Daptomycin can be increased when it is combined with Propafenone.
Propantheline	Daptomycin may decrease the excretion rate of Propantheline which could result in a higher serum level.
Proparacaine	The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Proparacaine.
Propiverine	Daptomycin may decrease the excretion rate of Propiverine which could result in a higher serum level.
Propofol	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Propofol.
Propoxycaine	The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Propoxycaine.
Propranolol	Daptomycin may decrease the excretion rate of Propranolol which could result in a higher serum level.
Propylthiouracil	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Propylthiouracil.
Prucalopride	Daptomycin may decrease the excretion rate of Prucalopride which could result in a higher serum level.
Pyrantel	Daptomycin may decrease the excretion rate of Pyrantel which could result in a higher serum level.
Pyrazinamide	Daptomycin may decrease the excretion rate of Pyrazinamide which could result in a higher serum level.
Pyridoxine	Daptomycin may decrease the excretion rate of Pyridoxine which could result in a higher serum level.
Pyrithione	Daptomycin may decrease the excretion rate of Pyrithione which could result in a higher serum level.
Quetiapine	Daptomycin may decrease the excretion rate of Quetiapine which could result in a higher serum level.
Quinethazone	Quinethazone may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Quinidine	Daptomycin may decrease the excretion rate of Quinidine which could result in a higher serum level.
Quinine	The serum concentration of Daptomycin can be increased when it is combined with Quinine.
Rabeprazole	Daptomycin may decrease the excretion rate of Rabeprazole which could result in a higher serum level.
Raltegravir	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Raltegravir.
Ramelteon	Daptomycin may decrease the excretion rate of Ramelteon which could result in a higher serum level.
Ranitidine	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ranitidine.
Ranolazine	The serum concentration of Daptomycin can be increased when it is combined with Ranolazine.
Rasagiline	Daptomycin may decrease the excretion rate of Rasagiline which could result in a higher serum level.
Regorafenib	The serum concentration of Daptomycin can be increased when it is combined with Regorafenib.
Relugolix	The serum concentration of Relugolix can be increased when it is combined with Daptomycin.
Reserpine	The serum concentration of Daptomycin can be increased when it is combined with Reserpine.
Resorcinol	Daptomycin may decrease the excretion rate of Resorcinol which could result in a higher serum level.
Revefenacin	The serum concentration of Revefenacin can be increased when it is combined with Daptomycin.

Ribavirin	Daptomycin may decrease the excretion rate of Ribavirin which could result in a higher serum level.
Ribostamycin	Daptomycin may decrease the excretion rate of Ribostamycin which could result in a higher serum level.
Rifamycin	The serum concentration of Daptomycin can be increased when it is combined with Rifamycin.
Rimegepant	The serum concentration of Rimegepant can be increased when it is combined with Daptomycin.
Riociguat	The serum concentration of Riociguat can be increased when it is combined with Daptomycin.
Ripretinib	The serum concentration of Daptomycin can be increased when it is combined with Ripretinib.
Risedronic acid	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Risedronic acid.
Ritonavir	The serum concentration of Daptomycin can be increased when it is combined with Ritonavir.
Rivaroxaban	The serum concentration of Rivaroxaban can be increased when it is combined with Daptomycin.
Rizatriptan	Daptomycin may decrease the excretion rate of Rizatriptan which could result in a higher serum level.
Rofecoxib	Rofecoxib may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Roflumilast	Daptomycin may decrease the excretion rate of Roflumilast which could result in a higher serum level.
Rolapitant	The serum concentration of Daptomycin can be increased when it is combined with Rolapitant.
Romidepsin	The serum concentration of Romidepsin can be increased when it is combined with Daptomycin.
Ropivacaine	The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Ropivacaine.
Rosiglitazone	Daptomycin may decrease the excretion rate of Rosiglitazone which could result in a higher serum level.
Rosuvastatin	The risk or severity of myopathy can be increased when Rosuvastatin is combined with Daptomycin.
Ruxolitinib	Daptomycin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Sacubitril	Daptomycin may decrease the excretion rate of Sacubitril which could result in a higher serum level.
Salbutamol	Daptomycin may decrease the excretion rate of Salbutamol which could result in a higher serum level.
Salicylamide	Salicylamide may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Salicylic acid	Salicylic acid may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Salmeterol	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Salmeterol.
Salmon calcitonin	Salmon calcitonin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Salsalate	Salsalate may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Sapropterin	The serum concentration of Daptomycin can be increased when it is combined with Sapropterin.
Saquinavir	The serum concentration of Daptomycin can be increased when it is combined with Saquinavir.
Sarecycline	The serum concentration of Daptomycin can be increased when it is combined with Sarecycline.
Saxagliptin	Daptomycin may decrease the excretion rate of Saxagliptin which could result in a higher serum level.
Secobarbital	Daptomycin may decrease the excretion rate of Secobarbital which could result in a higher serum level.
Selenious acid	Daptomycin may decrease the excretion rate of Selenious acid which could result in a higher serum level.
Selenium	Daptomycin may decrease the excretion rate of Selenium which could result in a higher serum level.
Selexipag	The serum concentration of Selexipag can be increased when it is combined with Daptomycin.
Selumetinib	The serum concentration of Selumetinib can be increased when it is combined with Daptomycin.
Sibutramine	Daptomycin may decrease the excretion rate of Sibutramine which could result in a higher serum level.
Sildenafil	The serum concentration of Daptomycin can be increased when it is combined with Sildenafil.
Silodosin	The serum concentration of Silodosin can be increased when it is combined with Daptomycin.
Simeprevir	The serum concentration of Daptomycin can be increased when it is combined with Simeprevir.
Simvastatin	The risk or severity of myopathy can be increased when Simvastatin is combined with Daptomycin.
Sirolimus	The serum concentration of Sirolimus can be increased when it is combined with Daptomycin.
Sitagliptin	The serum concentration of Sitagliptin can be increased when it is combined with Daptomycin.
Sodium acetate	Daptomycin may decrease the excretion rate of Sodium acetate which could result in a higher serum level.
Sodium aurothio	Daptomycin may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.
Sodium fluoride	Daptomycin may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.
Sodium sulfate	Daptomycin may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.
Sofosbuvir	The serum concentration of Sofosbuvir can be increased when it is combined with Daptomycin.
Solriamfetol	Daptomycin may decrease the excretion rate of Solriamfetol which could result in a higher serum level.
Somatotropin	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Somatotropin is combined with Daptomycin.
Sorafenib	The serum concentration of Daptomycin can be increased when it is combined with Sorafenib.
Sorbitol	Daptomycin may decrease the excretion rate of Sorbitol which could result in a higher serum level.
Sotagliflozin	The serum concentration of Daptomycin can be increased when it is combined with Sotagliflozin.
Sotorasib	The serum concentration of Daptomycin can be increased when it is combined with Sotorasib.
Spironolactone	Spironolactone may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Stavudine	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Stavudine.
Stiripentol	The excretion of Daptomycin can be decreased when combined with Stiripentol.
Streptomycin	Daptomycin may decrease the excretion rate of Streptomycin which could result in a higher serum level.
Strontium chloride	Daptomycin may decrease the excretion rate of Strontium chloride which could result in a higher serum level.
Sucralfate	Daptomycin may decrease the excretion rate of Sucralfate which could result in a higher serum level.
Sulbactam	Daptomycin may decrease the excretion rate of Sulbactam which could result in a higher serum level.
Sulfadiazine	Daptomycin may decrease the excretion rate of Sulfadiazine which could result in a higher serum level.
Sulfamethoxazole	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Sulfamethoxazole.
Sulfasalazine	Sulfasalazine may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Sulindac	Sulindac may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Sumatriptan	Daptomycin may decrease the excretion rate of Sumatriptan which could result in a higher serum level.
Suvorexant	The serum concentration of Daptomycin can be increased when it is combined with Suvorexant.
S Estrogens, A	Daptomycin may decrease the excretion rate of Synthetic Conjugated Estrogens, A which could result in a higher serum level.
S Estrogens, B	Daptomycin may decrease the excretion rate of Synthetic Conjugated Estrogens, B which could result in a higher serum level.
Tacrine	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Tacrine.
Tacrolimus	The serum concentration of Daptomycin can be increased when it is combined with Tacrolimus.
Tadalafil	Daptomycin may decrease the excretion rate of Tadalafil which could result in a higher serum level.
Talazoparib	The serum concentration of Talazoparib can be increased when it is combined with Daptomycin.
Tamoxifen	The serum concentration of Daptomycin can be increased when it is combined with Tamoxifen.
Tamsulosin	Daptomycin may decrease the excretion rate of Tamsulosin which could result in a higher serum level.
Tasimelteon	Daptomycin may decrease the excretion rate of Tasimelteon which could result in a higher serum level.
Tazemetostat	The serum concentration of Tazemetostat can be increased when it is combined with Daptomycin.
Technetium	Daptomycin may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.
Technetium	Daptomycin may decrease the excretion rate of Technetium Tc-99m mebrofenin which could result in a higher serum level.
Technetium	Daptomycin may decrease the excretion rate of Technetium Tc-99m oxidronate which could result in a higher serum level.
Technetium	Daptomycin may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level.
Technetium	The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Daptomycin.
Teduglutide	Daptomycin may decrease the excretion rate of Teduglutide which could result in a higher serum level.
Tegafur	Daptomycin may decrease the excretion rate of Tegafur which could result in a higher serum level.
Tegaserod	The serum concentration of Tegaserod can be increased when it is combined with Daptomycin.
Telaprevir	The serum concentration of Daptomycin can be increased when it is combined with Telaprevir.
Telavancin	Daptomycin may decrease the excretion rate of Telavancin which could result in a higher serum level.
Temazepam	Daptomycin may decrease the excretion rate of Temazepam which could result in a higher serum level.
Temozolomide	Daptomycin may decrease the excretion rate of Temozolomide which could result in a higher serum level.
Temsirolimus	The serum concentration of Daptomycin can be increased when it is combined with Temsirolimus.
Tenofovir alafenamide	Tenofovir alafenamide may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Tenofovir disoproxil	The serum concentration of Tenofovir disoproxil can be increased when it is combined with Daptomycin.
Tenoxicam	Tenoxicam may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Tepotinib	The serum concentration of Daptomycin can be increased when it is combined with Tepotinib.
Terbinafine	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Terbinafine.
Terbutaline	Daptomycin may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Testolactone	Daptomycin may decrease the excretion rate of Testolactone which could result in a higher serum level.
Testosterone	Daptomycin may decrease the excretion rate of Testosterone which could result in a higher serum level.
Testosterone cypionate	Daptomycin may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level.
Testosterone enanthate	Daptomycin may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level.
Testosterone	Daptomycin may decrease the excretion rate of Testosterone propionate which could result in a higher serum level.
Testosterone	Daptomycin may decrease the excretion rate of Testosterone undecanoate which could result in a higher serum level.

Tetracaine	The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Tetracaine.
Tetracycline	Daptomycin may decrease the excretion rate of Tetracycline which could result in a higher serum level.
Tetradecyl hydrogen	Daptomycin may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level.
Tezacaftor	The serum concentration of Tezacaftor can be increased when it is combined with Daptomycin.
Thiabendazole	Daptomycin may decrease the excretion rate of Thiabendazole which could result in a higher serum level.
Thiethylperazine	Daptomycin may decrease the excretion rate of Thiethylperazine which could result in a higher serum level.
Tiaprofenic acid	Tiaprofenic acid may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Ticagrelor	The serum concentration of Daptomycin can be increased when it is combined with Ticagrelor.
Ticlopidine	Daptomycin may decrease the excretion rate of Ticlopidine which could result in a higher serum level.
Tiludronic acid	Daptomycin may decrease the excretion rate of Tiludronic acid which could result in a higher serum level.
Timolol	Daptomycin may decrease the excretion rate of Timolol which could result in a higher serum level.
Tinidazole	Daptomycin may decrease the excretion rate of Tinidazole which could result in a higher serum level.
Tiopronin	Daptomycin may decrease the excretion rate of Tiopronin which could result in a higher serum level.
Tiotropium	Daptomycin may decrease the excretion rate of Tiotropium which could result in a higher serum level.
Tipranavir	The serum concentration of Daptomycin can be increased when it is combined with Tipranavir.
Tirofiban	Daptomycin may decrease the excretion rate of Tirofiban which could result in a higher serum level.
Tivozanib	The serum concentration of Tivozanib can be increased when it is combined with Daptomycin.
Tixocortol	Daptomycin may decrease the excretion rate of Tixocortol which could result in a higher serum level.
Tobramycin	The serum concentration of Tobramycin can be decreased when it is combined with Daptomycin.
Tocopherol	Daptomycin may decrease the excretion rate of Tocopherol which could result in a higher serum level.
Tolazamide	Daptomycin may decrease the excretion rate of Tolazamide which could result in a higher serum level.
Tolbutamide	Daptomycin may decrease the excretion rate of Tolbutamide which could result in a higher serum level.
Tolcapone	Daptomycin may decrease the excretion rate of Tolcapone which could result in a higher serum level.
Tolfenamic acid	Tolfenamic acid may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Tolmetin	Tolmetin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Tolterodine	Daptomycin may decrease the excretion rate of Tolterodine which could result in a higher serum level.
Tolvaptan	Tolvaptan may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Topiramate	Daptomycin may decrease the excretion rate of Topiramate which could result in a higher serum level.
Topotecan	The serum concentration of Topotecan can be increased when it is combined with Daptomycin.
Torasemide	Torasemide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Toremifene	The serum concentration of Daptomycin can be increased when it is combined with Toremifene.
Tositumomab	Daptomycin may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Trabectedin	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Trabectedin.
Tramadol	Daptomycin may decrease the excretion rate of Tramadol which could result in a higher serum level.
Trametinib	Daptomycin may decrease the excretion rate of Trametinib which could result in a higher serum level.
Trastuzumab	The serum concentration of Trastuzumab emtansine can be increased when it is combined with Daptomycin.
Triamcinolone	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Triamcinolone.
Triamterene	Triamterene may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Triazolam	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Triazolam.
Trichlormethiazide	Trichlormethiazide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Triethylenetetramine	Daptomycin may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.
Trifluridine	Daptomycin may decrease the excretion rate of Trifluridine which could result in a higher serum level.
Trilaciclib	The serum concentration of Trilaciclib can be increased when it is combined with Daptomycin.
Trimebutine	Daptomycin may decrease the excretion rate of Trimebutine which could result in a higher serum level.
Trimethoprim	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Trimethoprim.
Trimetrexate	Daptomycin may decrease the excretion rate of Trimetrexate which could result in a higher serum level.
Trimipramine	The serum concentration of Trimipramine can be increased when it is combined with Daptomycin.
Tropisetron	Daptomycin may decrease the excretion rate of Tropisetron which could result in a higher serum level.
Tucatinib	Tucatinib may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Typhoid vaccine	The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Daptomycin.
Ubidecarenone	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ubidecarenone.
Ubrogepant	The serum concentration of Ubrogepant can be increased when it is combined with Daptomycin.
Umbralisib	The serum concentration of Daptomycin can be increased when it is combined with Umbralisib.
Umeclidinium	The serum concentration of Umeclidinium can be increased when it is combined with Daptomycin.
Vaborbactam	Daptomycin may decrease the excretion rate of Vaborbactam which could result in a higher serum level.
Valaciclovir	Valaciclovir may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Valbenazine	Daptomycin may decrease the excretion rate of Valbenazine which could result in a higher serum level.
Valdecoxib	Valdecoxib may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Valganciclovir	Daptomycin may decrease the excretion rate of Valganciclovir which could result in a higher serum level.
Vancomycin	Daptomycin may decrease the excretion rate of Vancomycin which could result in a higher serum level.
Vandetanib	The serum concentration of Daptomycin can be increased when it is combined with Vandetanib.
Vardenafil	The serum concentration of Daptomycin can be increased when it is combined with Vardenafil.
Varenicline	Daptomycin may decrease the excretion rate of Varenicline which could result in a higher serum level.
Velpatasvir	The serum concentration of Daptomycin can be increased when it is combined with Velpatasvir.
Vemurafenib	The serum concentration of Daptomycin can be increased when it is combined with Vemurafenib.
Venetoclax	The serum concentration of Daptomycin can be increased when it is combined with Venetoclax.
Venlafaxine	Daptomycin may decrease the excretion rate of Venlafaxine which could result in a higher serum level.
Verapamil	The serum concentration of Daptomycin can be increased when it is combined with Verapamil.
Vibrio cholerae	The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Daptomycin.
Vilanterol	Daptomycin may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Viloxazine	Daptomycin may decrease the excretion rate of Viloxazine which could result in a higher serum level.
Vinblastine	The serum concentration of Vinblastine can be increased when it is combined with Daptomycin.
Vincristine	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Vincristine.
Vinflunine	The serum concentration of Vinflunine can be increased when it is combined with Daptomycin.
Voclosporin	The serum concentration of Daptomycin can be increased when it is combined with Voclosporin.
Vorapaxar	The serum concentration of Daptomycin can be increased when it is combined with Vorapaxar.
Vortioxetine	Daptomycin may decrease the excretion rate of Vortioxetine which could result in a higher serum level.
Voxilaprevir	The serum concentration of Daptomycin can be increased when it is combined with Voxilaprevir.
Warfarin	Daptomycin may decrease the excretion rate of Warfarin which could result in a higher serum level.
Zaleplon	Daptomycin may decrease the excretion rate of Zaleplon which could result in a higher serum level.
Zanamivir	Daptomycin may decrease the excretion rate of Zanamivir which could result in a higher serum level.
Zidovudine	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Zidovudine.
Zonisamide	The serum concentration of Daptomycin can be increased when it is combined with Zonisamide.

Pregnancy and Lactation

AU TGA pregnancy category: D
US FDA pregnancy category: Not assigned.

Pregnancy

Based on findings from animal studies and its mechanism of action, this drug can cause fetal harm when administered to a pregnant woman.
Verify negative pregnancy status in females of reproductive potential prior to initiating therapy. Advise females of reproductive potential to use effective contraception during therapy and for at least 6 months after. Because of the potential for genotoxicity, advise males with female partners of reproductive potential to use effective contraception during therapy and for 3 months after. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus.

Lactation

No information is available on the use of this drug during breastfeeding. Most experts consider breastfeeding contraindicated during maternal antineoplastic therapy. The effects in the nursing infant are unknown. The manufacturer recommends that breastfeeding be discontinued during therapy and for at least 14 days after.

How should this medicine be used?

Dactinomycin comes as a powder to be mixed with liquid to be injected intravenously (into a vein) by a doctor or nurse in a medical facility. The length of treatment depends on the type of cancer you have, the types of other drugs you are taking, and how well your body responds to treatment. Your doctor may need to stop or delay your treatment if you experience certain side effects. Dactinomycin may also be injected by a doctor directly into a specific the part of the body or the organ to treat the area where a tumor is located. Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient.

Dactinomycin is also sometimes used to treat a type of cancer of the ovaries (a cancer that begins in the female reproductive organs where eggs are formed). Talk to your doctor about the risks of using this medication for your condition. This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

What special precautions should I follow?

Before receiving dactinomycin,

tell your doctor and pharmacist if you are allergic to dactinomycin, any other medications, or any of the ingredients in dactinomycin injection. Ask your pharmacist for a list of the ingredients.
tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take.
tell your doctor if you have chickenpox or herpes zoster (shingles). Your doctor will probably not want you to receive dactinomycin injection.
tell your doctor if you have previously received or are currently receiving radiation therapy.
tell your doctor if you are pregnant, plan to become pregnant, or are breast-feeding. You should not become pregnant or breast-feed while you are receiving dactinomycin. If you become pregnant while receiving dactinomycin, call your doctor. Dactinomycin may harm the fetus.
do not have any vaccinations without talking to your doctor.

References

https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050682s025lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/050682s033lbl.pdf
https://pubchem.ncbi.nlm.nih.gov/compound/Dactinomycin
https://pubchem.ncbi.nlm.nih.gov/compound/2019
https://en.wikipedia.org/wiki/Dactinomycin
https://go.drugbank.com/drugs/DB00080
https://medlineplus.gov/druginfo/meds/a682224.html
https://www.mayoclinic.org/drugs-supplements/dactinomycin-intravenous-route/side-effects/drg-20063277?p=1
https://www.drugs.com/mtm/dactinomycin.html
https://www.webmd.com/drugs/2/drug-19921/dactinomycin-intravenous/details/list-contraindications
ChEMBL

http://www.ebi.ac.uk/Information/termsofuse.html

https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1554/

ChEMBL Protein Target Tree

https://www.ebi.ac.uk/chembl/g/#browse/targets
Comparative Toxicogenomics Database (CTD)

http://ctdbase.org/about/legal.jsp

Dactinomycin

https://ctdbase.org/detail.go?type=chem&acc=D003609
Drug Gene Interaction database (DGIdb)

http://www.dgidb.org/downloads

DACTINOMYCIN

https://www.dgidb.org/drugs/DACTINOMYCIN
DrugBank

https://www.drugbank.ca/legal/terms_of_use

Dactinomycin

https://www.drugbank.ca/drugs/DB00970
Therapeutic Target Database (TTD)

Dactinomycin

http://idrblab.net/ttd/data/drug/details/D0P8IV
CAMEO Chemicals

https://cameochemicals.noaa.gov/help/reference/terms_and_conditions.htm?d_f=false

ACTINOMYCIN D

https://cameochemicals.noaa.gov/chemical/19722

CAMEO Chemical Reactivity Classification

https://cameochemicals.noaa.gov/browse/react
ChemIDplus

LICENSE

https://www.nlm.nih.gov/copyright.html

Dactinomycin [USAN:USP:INN:BAN]

https://chem.nlm.nih.gov/chemidplus/sid/0000050760

ChemIDplus Chemical Information Classification

https://chem.nlm.nih.gov/chemidplus/
EPA DSSTox

LICENSE

https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources

Actinomycin D

https://comptox.epa.gov/dashboard/DTXSID9020031

CompTox Chemicals Dashboard Chemical Lists

https://comptox.epa.gov/dashboard/chemical-lists/
European Chemicals Agency (ECHA)

https://echa.europa.eu/web/guest/legal-notice

Dactinomycin

https://echa.europa.eu/substance-information/-/substanceinfo/100.000.058

Dactinomycin

https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/88782
FDA Global Substance Registration System (GSRS)

https://www.fda.gov/about-fda/about-website/website-policies#linking

DACTINOMYCIN

https://gsrs.ncats.nih.gov/ginas/app/beta/substances/1CC1JFE158
Hazardous Substances Data Bank (HSDB)

DACTINOMYCIN

https://pubchem.ncbi.nlm.nih.gov/source/hsdb/3220
Human Metabolome Database (HMDB)

http://www.hmdb.ca/citing

Dactinomycin

http://www.hmdb.ca/metabolites/HMDB0015105

HMDB0015105_msms_2253147

https://hmdb.ca/metabolites/HMDB0015105#spectra
ChEBI

Actinomycin D

http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:27666

ChEBI Ontology

http://www.ebi.ac.uk/chebi/userManualForward.do#ChEBI%20Ontology
FDA Pharm Classes

https://www.fda.gov/about-fda/about-website/website-policies#linking

DACTINOMYCIN

https://dailymed.nlm.nih.gov/dailymed/browse-drug-classes.cfm

FDA Pharmacological Classification

https://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162549.htm
LiverTox

LICENSE

https://www.nlm.nih.gov/copyright.html

Dactinomycin

https://www.ncbi.nlm.nih.gov/books/n/livertox/Dactinomycin/
LOTUS – the natural products occurrence database

https://lotus.nprod.net/

dactinomycin

https://www.wikidata.org/wiki/Q186127

LOTUS Tree

https://lotus.naturalproducts.net/
NCI Thesaurus (NCIt)

https://www.cancer.gov/policies/copyright-reuse

https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C412

NCI Thesaurus Tree

https://ncit.nci.nih.gov
CCSbase

https://ccsbase.net/
ClinicalTrials.gov

https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use

https://clinicaltrials.gov/
DailyMed

LICENSE

https://www.nlm.nih.gov/copyright.html

DACTINOMYCIN

https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=DACTINOMYCIN
Drug Induced Liver Injury Rank (DILIrank) Dataset

https://www.fda.gov/about-fda/about-website/website-policies#linking

dactinomycin

https://www.fda.gov/science-research/liver-toxicity-knowledge-base-ltkb/drug-induced-liver-injury-rank-dilirank-dataset
The Natural Products Atlas

https://www.npatlas.org/terms

Actinomycin D

https://www.npatlas.org/explore/compounds/NPA007563

The Natural Products Atlas Classification

https://www.npatlas.org/
EU Clinical Trials Register

https://www.clinicaltrialsregister.eu/
FDA Orange Book

https://www.fda.gov/about-fda/about-website/website-policies#linking

https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
National Drug Code (NDC) Directory

https://www.fda.gov/about-fda/about-website/website-policies#linking

DACTINOMYCIN

https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory
International Agency for Research on Cancer (IARC)

https://publications.iarc.fr/Terms-Of-Use

Actinomycin D

https://monographs.iarc.who.int/list-of-classifications

IARC Classification

https://www.iarc.fr/
MassBank of North America (MoNA)

LICENSE

The content of the MoNA database is licensed under CC BY 4.0.

https://mona.fiehnlab.ucdavis.edu/documentation/license

Actinomycin D

https://mona.fiehnlab.ucdavis.edu/spectra/browse?query=compound.metaData%3Dq%3D%27name%3D%3D%22InChIKey%22%20and%20value%3D%3D%22RJURFGZVJUQBHK-IIXSONLDSA-N%22%27
NCI Cancer Drugs

LICENSE

https://www.cancer.gov/policies/copyright-reuse

Cosmegen (Dactinomycin)

https://www.cancer.gov/about-cancer/treatment/drugs/dactinomycin
NIPH Clinical Trials Search of Japan

https://rctportal.niph.go.jp/en/
NLM RxNorm Terminology

https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html

dactinomycin

https://rxnav.nlm.nih.gov/id/rxnorm/3100
PubChem

https://pubchem.ncbi.nlm.nih.gov
Springer Nature

https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=90114615-889043108
WHO Anatomical Therapeutic Chemical (ATC) Classification

https://www.whocc.no/copyright_disclaimer/

https://www.whocc.no/atc/

ATC Code

https://www.whocc.no/atc_ddd_index/
WHO Model Lists of Essential Medicines

https://www.who.int/about/who-we-are/publishing-policies/copyright

Dactinomycin

https://list.essentialmeds.org/medicines/83
Wikidata

LICENSE

CCZero

https://creativecommons.org/publicdomain/zero/1.0/

Dactinomycin

https://www.wikidata.org/wiki/Q186127
Wiley

https://pubchem.ncbi.nlm.nih.gov/substance/?source=wiley&sourceid=64721
Medical Subject Headings (MeSH)

https://www.nlm.nih.gov/copyright.html

Dactinomycin

https://www.ncbi.nlm.nih.gov/mesh/68003609

MeSH Tree

http://www.nlm.nih.gov/mesh/meshhome.html

Anti-Bacterial Agents

https://www.ncbi.nlm.nih.gov/mesh/68000900

Nucleic Acid Synthesis Inhibitors

https://www.ncbi.nlm.nih.gov/mesh/68019384

Protein Synthesis Inhibitors

https://www.ncbi.nlm.nih.gov/mesh/68011500

Antibiotics, Antineoplastic

https://www.ncbi.nlm.nih.gov/mesh/68000903
UN Globally Harmonized System of Classification and Labelling of Chemicals (GHS)

GHS Classification Tree

http://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html
NORMAN Suspect List Exchange

https://creativecommons.org/licenses/by/4.0/

NORMAN Suspect List Exchange Classification

https://www.norman-network.com/nds/SLE/
EPA Substance Registry Services

LICENSE

https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources

EPA SRS List Classification

https://sor.epa.gov/sor_internet/registry/substreg/LandingPage.do
PATENTSCOPE (WIPO)

SID 388454111

https://pubchem.ncbi.nlm.nih.gov/substance/388454111
NCBI

https://www.ncbi.nlm.nih.gov/projects/linkout

Continue through a complete learning pathway

Move from understanding the topic to symptoms, tests, treatment, medicines, monitoring, and prevention.

Search the complete library

Conditions & Diseases

Background, symptoms, causes, diagnosis, and care.

Explore this library

Tests & Investigations

Laboratory, imaging, screening, and diagnostic education.

Explore this library

Medicines

Uses, safety, monitoring, and related medicine knowledge.

Explore this library

Cancer Knowledge

Cancer types, screening, oncology, and treatment education.

Explore this library

Safety note: This is not a prescription or diagnosis. For severe symptoms, pregnancy danger signs, children with serious illness, chest pain, breathing difficulty, stroke-like weakness, or major injury, seek urgent care.

Which doctor may help?

Start with a registered doctor or the nearest qualified health center.

What to tell the doctor

Write when the problem started and how it changed.
Bring old prescriptions, investigation reports, and current medicines.
Write allergies, pregnancy status, diabetes, kidney/liver disease, and major past illnesses.
Bring one family member if the patient is weak, elderly, confused, or a child.

Questions to ask

What is the most likely cause of my symptoms?
Which danger signs mean I should go to hospital quickly?
Which tests are necessary now, and which can wait?
How should I take medicines safely and what side effects should I watch for?
When should I come for follow-up?

Tests to discuss

Vital signs: temperature, pulse, blood pressure, oxygen saturation
Basic physical examination by a clinician
CBC, urine test, blood sugar, or imaging only when clinically needed

Avoid these mistakes

Do not use antibiotics, steroid tablets/injections, or strong painkillers without proper medical advice.
Do not hide pregnancy, kidney disease, ulcer, allergy, or blood thinner use.
Do not delay emergency care when danger signs are present.

Medicine safety and first-aid guide

This section is for patient education only. It does not replace a doctor, pharmacist, or emergency care.

Safe first steps

Avoid heavy lifting, sudden bending, and prolonged bed rest.
Use comfortable posture and gentle movement as tolerated.
Discuss physiotherapy, X-ray, or MRI only when clinically needed.

OTC medicine safety

For mild back pain, pain-relief medicine may be discussed with a doctor or pharmacist.
Avoid repeated painkiller use if you have kidney disease, stomach ulcer, uncontrolled blood pressure, or are taking blood thinners.

Avoid these mistakes

Do not start antibiotics without a proper medical decision.
Do not use steroid tablets or injections casually for quick relief.
Do not delay emergency care because of home remedies.

Get urgent help if

Back pain with leg weakness, numbness around private area, loss of urine/stool control, fever, cancer history, or major injury needs urgent care.

Medicine names, dose, and timing must be decided by a qualified clinician or pharmacist after checking age, pregnancy, allergy, other diseases, and current medicines.

For rural patients and family caregivers

Patient health record and symptom diary

Write your symptoms, medicines already taken, test results, and questions before visiting a doctor. This note stays on your device unless you print or copy it.

Doctor to discuss: Medicine doctor / pediatrician for children / qualified clinician

Tests to discuss with doctor

Temperature chart and hydration assessment
CBC with platelet count if fever persists or dengue/other infection is possible
Urine test, malaria/dengue tests, chest evaluation, or blood culture only when clinically indicated

Questions to ask

What is the most likely cause of my symptoms?
Which warning signs mean I should go to emergency care?
Which tests are really needed now?
Which medicines are safe for my age, pregnancy status, allergy, kidney/liver/stomach condition, and current medicines?
Do I need antibiotics, or is this more likely viral?

Emergency warning signs such as chest pain, severe breathing difficulty, sudden weakness, confusion, severe dehydration, major injury, or loss of bladder/bowel control need urgent medical care. Do not wait for online information.

Go to emergency care if you notice:

Severe or rapidly worsening symptoms
Breathing difficulty, chest pain, fainting, confusion, severe weakness, major injury, or severe dehydration

Doctor / service to discuss: Qualified healthcare provider; specialist depends on symptoms and examination.

Step 1
Check danger signs first

If danger signs are present, seek emergency care and do not wait for online information.
Step 2
Record the symptom story

Write when symptoms started, severity, medicines already taken, allergies, pregnancy status, and test results.
Step 3
Visit a qualified clinician

A doctor, nurse, or qualified healthcare provider can examine you and decide which tests or treatment are needed.
Step 4
Do only useful tests

Do tests after clinical assessment. Avoid unnecessary tests, random antibiotics, or repeated medicines without diagnosis.
Step 5
Follow up and return early if worse

If symptoms worsen, new warning signs appear, or treatment is not helping, return for review quickly.

Rural patient practical tips

Take a written symptom diary and all previous prescriptions/test reports.
Do not hide medicines already taken, even herbal or over-the-counter medicines.
Ask which warning signs mean urgent referral to hospital.

This roadmap is for education. A real diagnosis and treatment plan requires history, examination, and clinical judgment.

Read, save, and share this guide

Article Summary

Key Takeaways

RX Patient Tools

Mechanism of Action

Indications

Use in Cancer

Contraindications

Dosage?

Wilms’ Tumor

Rhabdomyosarcoma

Ewing’s Sarcoma

Testicular Cancer

Trophoblastic Disease

Solid Tumors

Usual Pediatric Dose

Wilms’ Tumor

Rhabdomyosarcoma

Ewing’s Sarcoma

Testicular Cancer

Trophoblastic Disease

Dose Adjustments

Side Effects

The Most Common

More common

Rare

Drug Interaction

Pregnancy and Lactation

Pregnancy

Lactation

How should this medicine be used?

What special precautions should I follow?

Before receiving dactinomycin,

More on this topic

Related medical topics

Related Articles

Prepare before seeing a doctor

Which doctor may help?

What to tell the doctor

Questions to ask

Tests to discuss

Avoid these mistakes

Medicine safety and first-aid guide

Safe first steps

OTC medicine safety

Avoid these mistakes

Get urgent help if

Patient health record and symptom diary

Care roadmap for: Dactinomycin – Uses, Dosage, Side Effects, Interaction

Check danger signs first

Record the symptom story

Visit a qualified clinician

Do only useful tests

Follow up and return early if worse

To Get Daily Health Newsletter

Dosage